Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Several other research firms also recently weighed in on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Thursday, October 31st.

Abeona Therapeutics Trading Down 0.1 %

NASDAQ ABEO opened at $6.10 on Tuesday. The business’s fifty day moving average is $6.16 and its 200-day moving average is $5.21. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48. The stock has a market capitalization of $264.22 million, a price-to-earnings ratio of -2.40 and a beta of 1.52. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.42). Equities research analysts predict that Abeona Therapeutics will post -1.28 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ABEO. Acadian Asset Management LLC bought a new stake in shares of Abeona Therapeutics during the 1st quarter worth $91,000. Western Standard LLC lifted its position in Abeona Therapeutics by 68.5% in the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock worth $9,871,000 after buying an additional 553,377 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in Abeona Therapeutics in the second quarter worth approximately $7,420,000. Bank of New York Mellon Corp grew its position in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 2,434 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after acquiring an additional 429,456 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.